Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Given Consensus Recommendation of “Buy” by Analysts

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) has been given an average rating of “Buy” by the six brokerages that are covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $37.17.

Several research firms recently issued reports on KNSA. Wedbush reissued an “outperform” rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, February 25th. Citigroup assumed coverage on Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a “buy” rating and a $40.00 price objective for the company.

Kiniksa Pharmaceuticals Stock Performance

NASDAQ:KNSA opened at $22.97 on Thursday. The firm has a market capitalization of $1.67 billion, a price-to-earnings ratio of -164.06 and a beta of 0.48. Kiniksa Pharmaceuticals has a 52-week low of $16.56 and a 52-week high of $28.15. The stock has a fifty day moving average of $20.05 and a 200 day moving average of $22.10.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The business had revenue of $122.50 million for the quarter, compared to the consensus estimate of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. Kiniksa Pharmaceuticals’s quarterly revenue was up 46.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.35 EPS. Equities analysts forecast that Kiniksa Pharmaceuticals will post -0.55 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Mark Ragosa sold 36,372 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $22.25, for a total transaction of $809,277.00. Following the completion of the sale, the chief financial officer now directly owns 22,958 shares in the company, valued at $510,815.50. This represents a 61.30 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Eben Tessari sold 14,000 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $19.57, for a total value of $273,980.00. Following the sale, the chief operating officer now owns 81,975 shares of the company’s stock, valued at $1,604,250.75. This represents a 14.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 73,423 shares of company stock valued at $1,541,812 over the last 90 days. Insiders own 54.57% of the company’s stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

Several institutional investors have recently bought and sold shares of KNSA. Quarry LP purchased a new stake in Kiniksa Pharmaceuticals during the 3rd quarter valued at about $50,000. Lazard Asset Management LLC purchased a new stake in Kiniksa Pharmaceuticals during the 4th quarter valued at about $61,000. KLP Kapitalforvaltning AS purchased a new stake in Kiniksa Pharmaceuticals during the 4th quarter valued at about $158,000. Bellevue Group AG purchased a new stake in Kiniksa Pharmaceuticals during the 4th quarter valued at about $160,000. Finally, Tower Research Capital LLC TRC raised its position in Kiniksa Pharmaceuticals by 117.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company’s stock valued at $168,000 after purchasing an additional 4,575 shares during the last quarter. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.